Therapeutic combinations and methods for treating neoplasia
OwnerSimon T. Barry, Simon HOLLINGSWORTHinventors
Life of this patent
Estimating the term…
Abstract
The disclosure features a CXCR2 antagonist in combination with a checkpoint inhibitor (e.g., an anti-CTLA-4 antibody or an anti-PD-L1 antibody) and methods of using the combination to enhance anti-tumor activity in a subject.
Claims26
A method of reducing tumor burden in a subject, the method comprising administering a CXCR2 antagonist and an immunomodulatory agent selected from the group consisting of an anti-PD-L1 antibody and an anti-CTLA4 antibody to a subject.
A method of increasing an anti-tumor immune response in a subject, the method comprising administering a CXCR2 antagonist and an immunomodulatory agent selected from the group consisting of an anti-PD-L1 antibody and an anti-CTLA4 antibody to a subject.
A method of treating a tumor in a subject, the method comprising administering a CXCR2 antagonist and an immunomodulatory agent selected from the group consisting of an anti-PD-L1 antibody and an anti-CTLA4 antibody to a subject.
A kit for increasing anti-tumor activity, the kit comprising a CXCR2 antagonist and an immunomodulatory agent selected from the group consisting of an anti-PD-L1 antibody and an anti-CTLA4 antibody.
Dependencies are inferred from the claim text.